nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

31.03.2016 | Original Article

Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands

verfasst von: Johanna C. Klein, Clarissa A. Wild, Stephan Lang, Sven Brandau

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Synthetic toll-like receptor (TLR) ligands stimulate defined immune cell subsets and are currently tested as novel immunotherapeutic agents against cancer with, however, varying clinical efficacy. Recent data showed the expression of TLR receptors also on tumor cells. In this study we investigated immunological events associated with the induction of tumor cell death by poly(I:C) and imiquimod. A human head and neck squamous cell carcinoma (HNSCC) cell line was exposed to poly(I:C) and imiquimod, which were delivered exogenously via culture medium or via electroporation. Cell death and cell biological consequences thereof were analyzed. For in vivo analyses, a human xenograft and a syngeneic immunocompetent mouse model were used. Poly(I:C) induced cell death only if delivered by electroporation into the cytosol. Cell death induced by poly(I:C) resulted in cytokine release and activation of monocytes in vitro. Monocytes activated by the supernatant of cancer cells previously exposed to poly(I:C) recruited significantly more Th1 cells than monocytes exposed to control supernatants. If delivered exogenously, imiquimod also induced tumor cell death and some release of interleukin-6, but cell death was not associated with release of Th1 cytokines, interferons, monocyte activation and Th1 recruitment. Interestingly, intratumoral injection of poly(I:C) triggered tumor cell death in tumor-bearing mice and reduced tumor growth independent of TLR signaling on host cells. Imiquimod did not affect tumor size. Our data suggest that common cancer therapeutic RNA compounds can induce functionally diverse types of cell death in tumor cells with implications for the use of TLR ligands in cancer immunotherapy.

Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML (1999) Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 41:1002–1007CrossRefPubMed

Fleming CJ, Bryden AM, Evans A, Dawe RS, Ibbotson SH (2004) A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol 151:485–488CrossRefPubMed

Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S, Lee JH (2005) Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 141:467–473CrossRefPubMed

Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G (2012) Trial watch: FDA-approved toll-like receptor agonists for cancer therapy. Oncoimmunology 1:894–907CrossRefPubMedPubMedCentral

Amos SM, Pegram HJ, Westwood JA, John LB, Devaud C, Clarke CJ, Restifo NP, Smyth MJ, Darcy PK, Kershaw MH (2011) Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother 60:671–683CrossRefPubMedPubMedCentral

Adams S (2009) Toll-like receptor agonists in cancer therapy. Immunotherapy 1:949–964CrossRefPubMedPubMedCentral

Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196–200CrossRefPubMed

Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, Seto Y, Yamamoto A, Seya T (2003) Subcellular localization of toll-like receptor 3 in human dendritic cells. J Immunol 171:3154–3162CrossRefPubMed

Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, Tahara H, Inoue N, Seya T (2012) Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci USA 109:2066–2071CrossRefPubMedPubMedCentral

10.

Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature 413:732–738CrossRefPubMed

11.

Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, Diamond MS, Colonna M (2006) Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci USA 103:8459–8464CrossRefPubMedPubMedCentral

12.

Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5:730–737CrossRefPubMed

13.

Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526–1529CrossRefPubMed

14.

Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C (2012) Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol 7:29–54CrossRefPubMed

15.

Pinto A, Morello S, Sorrentino R (2011) Lung cancer and toll-like receptors. Cancer Immunol Immunother 60:1211–1220CrossRefPubMed

16.

Rydberg C, Mansson A, Uddman R, Riesbeck K, Cardell LO (2009) Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas. Immunology 128:e600–e611CrossRefPubMedPubMedCentral

17.

Schön M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, Benninghoff B, Slade HB, Gollnick H, Schön MP (2003) Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95:1138–1149CrossRefPubMed

18.

Kübler K, tho Pesch C, Gehrke N, Riemann S, Dassler J, Coch C, Landsberg J, Wimmenauer V, Pölcher M, Rudlowski C, Tüting T, Kuhn W, Hartmann G, Barchet W (2011) Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells. Eur J Immunol 41:3028–3039CrossRefPubMed

19.

Qu J, Hou Z, Han Q, Jiang W, Zhang C, Tian Z, Zhang J (2014) Intracellular poly(I:C) initiated gastric adenocarcinoma cell apoptosis and subsequently ameliorated NK cell functions. J Interferon Cytokine Res 34:52–59CrossRefPubMedPubMedCentral

20.

Besch R, Poeck H, Hohenauer T, Senft D, Hacker G, Berking C, Hornung V, Endres S, Ruzicka T, Rothenfusser S, Hartmann G (2009) Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 119:2399–2411PubMedPubMedCentral

21.

Schön MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC, Gollnick H, Schön M (2004) Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 122:1266–1276CrossRefPubMed

22.

Smith EB, Schwartz M, Kawamoto H, You X, Hwang D, Liu H, Scherr DS (2007) Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol 177:2347–2351CrossRefPubMed

23.

Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH, Abreu MT (2007) Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133:1869–1881CrossRefPubMedPubMedCentral

24.

Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72CrossRefPubMed

25.

Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, Shen H, Zhu X (2010) Reduced expression of toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res 29:92CrossRefPubMedPubMedCentral

26.

Williams R, Lee DW, Elzey BD, Anderson ME, Hostager BS, Lee JH (2009) Preclinical models of HPV + and HPV − HNSCC in mice: an immune clearance of HPV + HNSCC. Head Neck 31:911–918CrossRefPubMed

27.

Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, Crozat K, Mudd S, Mann N, Sovath S, Goode J, Shamel L, Herskovits AA, Portnoy DA, Cooke M, Tarantino LM, Wiltshire T, Steinberg BE, Grinstein S, Beutler B (2006) The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via toll-like receptors 3, 7 and 9. Nat Immunol 7:156–164CrossRefPubMed

28.

Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM (1994) In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 179:1215–1224CrossRefPubMed

29.

Kovalcsik E, Lowe K, Fischer M, Dalgleish A, Bodman-Smith MD (2011) Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activation. Cancer Immunol Immunother 60:1609–1624CrossRefPubMed

30.

Basith S, Manavalan B, Yoo TH, Kim SG, Choi S (2012) Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res 35:1297–1316CrossRefPubMed

31.

Cheng YS, Xu F (2010) Anticancer function of polyinosinic–polycytidylic acid. Cancer Biol Ther 10:1219–1223CrossRefPubMed

32.

Peng S, Geng J, Sun R, Tian Z, Wei H (2009) Polyinosinic–polycytidylic acid liposome induces human hepatoma cells apoptosis which correlates to the up-regulation of RIG-I like receptors. Cancer Sci 100:529–536CrossRefPubMed

33.

Tong CC, Kao J, Sikora AG (2012) Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. Immunol Res 54:266–274CrossRefPubMed

34.

Lion E, Anguille S, Berneman ZN, Smits EL, Van Tendeloo VF (2011) Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC. PLoS ONE 6:e20952CrossRefPubMedPubMedCentral

35.

Kono H, Rock KL (2008) How dying cells alert the immune system to danger. Nat Rev Immunol 8:279–289CrossRefPubMedPubMedCentral

36.

Rock KL, Kono H (2008) The inflammatory response to cell death. Annu Rev Pathol 3:99–126CrossRefPubMedPubMedCentral

37.

Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G (2008) Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 15:3–12CrossRefPubMed

38.

Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, Mendiboure J, Pignon JP, Jooste V, van Endert P, Ducreux M, Zitvogel L, Piard F, Kroemer G (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29:482–491CrossRefPubMed

39.

Pries R, Hogrefe L, Xie L, Frenzel H, Brocks C, Ditz C, Wollenberg B (2008) Induction of c-Myc-dependent cell proliferation through toll-like receptor 3 in head and neck cancer. Int J Mol Med 21:209–215PubMed

40.

Pries R, Wulff S, Wollenberg B (2008) Toll-like receptor modulation in head and neck cancer. Crit Rev Immunol 28:201–213CrossRefPubMed

41.

Luo Q, Hu S, Yan M, Sun Z, Chen W, Chen F (2012) Activation of toll-like receptor 3 induces apoptosis of oral squamous carcinoma cells in vitro and in vivo. Int J Biochem Cell Biol 44:1266–1275CrossRefPubMed

Titel: Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands
verfasst von: Johanna C. Klein
Clarissa A. Wild
Stephan Lang
Sven Brandau
Publikationsdatum: 31.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 6/2016
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-016-1828-3

Springer Medizin

Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

2′–5′ Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons

A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome

Endostatin inhibits the growth and migration of 4T1 mouse breast cancer cells by skewing macrophage polarity toward the M1 phenotype

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma

Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma

Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors “A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome”

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie